May 17, 2019– A recent study highlights how the 340B drug pricing program helps a safety-net hospital provide critical treatment to patients with Hepatitis C (HCV) and improve health outcomes. Published in the journal PLOS ONE, researchers at Boston Medical Center (BMC) found that the hospital’s 340B savings enabled them to operate a primary-care based multidisciplinary HCV … [Read more...]